Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT04664686

Rate or Rhythm Control in CRT: the RHYTHMIC Study

Rate or Rhythm Control in CRT: the RHYTHMIC Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT04664686.

📅 25 Mar 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT04664686
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Start
2021-10-19
ClinicaliQ Trial Snapshot
  • Rate or Rhythm Control in CRT: the RHYTHMIC Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT04664686.
  • 70 patients with heart failure, AF and CRT with BiV.
  • Sponsor: Guy's and St Thomas' NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

70 patients with heart failure, AF and CRT with BiV

Eligibility Snapshot
  • : * Ability to provide informed consent to participate and willing to comply with the clinical investigation plan and follow-up schedule. * QRS duration >120ms on surface ECG, severe left ventricular systolic impairment (EF≤35%) and clinical symptoms of heart failure despite optimum medical therapy (NYHA class II-IV) at time of CRT implant or upgrade * Successful CRT implant or upgrade including atrial lead * Biventricular pacing percentage

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure
Cardiology / Cardiovascular · 30 Mar 2026
This EMA guideline addresses EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure in Cardiology / Cardiovascular. Use it to…
View guideline →
Clinical Brief
Women’s voices to be at the heart of renewed health strategy
Cardiology / Cardiovascular · NHS England · 14 Apr 2026
Women's Health Strategy will be renewed with enhanced mechanisms to centre female patient voices in healthcare planning and delivery Strategy aims to…
View brief →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
The struggle to get hold of medication in England is set to get worse
Cardiology / Cardiovascular · BBC Health · 01 May 2026
Drug supply shortages are affecting multiple therapeutic areas – patients with cardiovascular disease, stroke prevention, ophthalmology, and psychiatric conditions are currently experiencing…
View brief →